Skip to Main Content
Home Books Internal Medicine: A Guide to Clinical Therapeutics

Chapter 1. Acute Coronary Syndromes

Ola Oyetayo

Definitions (Circulation 2004;110:e82; Circulation 2007;116:e148; Circulation 2008;117:296)

  • Acute coronary syndrome (ACS): umbrella term, includes all clinical syndromes compatible with acute myocardial ischemia arising from an imbalance in myocardial oxygen supply & demand
  • Classified based on ECG results into ST-segment elevation ACS (STE myocardial infarction STEMI) & non-STE ACS (NSTEACS)
  • NSTEACS classified based on cardiac biomarkers (troponins) into NSTEMI or unstable angina (UA)

Etiology (Circulation 2004;110:e82; Circulation 2007;116:e148; Circulation 2008;117:296)

  • Most common cause is reduced myocardial perfusion due to coronary artery narrowing caused by thrombus formation on a disrupted atherosclerotic plaque
  • In NSTEACS, coronary artery is partially occluded by thrombus; in STEMI, thrombus typically totally occlusive

(N Engl J Med 2009;360:2237; Lancet 2008;372:570; N Engl J Med 2004;350:277; N Engl J Med 2007;357:2482)

  • Atherosclerotic plaque rupture exposes thrombogenic components of the plaque
  • Vulnerable plaques contain numerous inflammatory cells, large lipid core, & a thin fibrous cap
  • Platelets arrive & adhere to the site of rupture → platelets release mediators such as epinephrine, adenosine diphosphate (ADP), thromboxane A2 (TXA2), & thrombin → activate & maintain platelet response
  • Activated platelets are also source of inflammatory mediators: CD40 ligand, P-selectin, & IL-1β
  • Tissue factor initiates extrinsic clotting cascade → enzymatic conversion of fibrinogen to fibrin by thrombin; further stabilizes the thrombus (now cross-linked platelets & fibrin)

Table 1-1 TIMI Risk Score for NSTEACS (JAMA 2000;284:835)
View Table||Download (.pdf)
Table 1-1 TIMI Risk Score for NSTEACS (JAMA 2000;284:835)

Predictor Variables

Points

Risk Category

TIMI Risk Score

14d Rate of MACE (%)

Age ≥65

1

Low risk

0–1

4.7

ST-segment deviation

1

2

8.3

Known CAD (stenosis ≥50%)

1

Medium risk

3

13.2

Aspirin use in past 7d

1

4

19.9

Recent (≤24h) severe angina

1

High risk

5

26.2

Positive cardiac biomarkers

1

6–7

40.9

≥3 CAD risk factors (FH, HTN, ↑chol, DM, active smoking)

1

TIMI risk score (0–7) is calculated by totaling points derived from the predictor variables & assigning a risk category.

FH, family history; HTN, hypertension; DM, diabetes mellitus; CAD, coronary artery disease; MACE, major adverse cardiac event (death, MI, or urgent revascularization).

Risk Stratification (Am Heart J 2009;158:193; JAMA 2000;284:835) guides ACS pharmacotherapy & management

  • STEMI patients have the highest risk of in-hospital & short-term major adverse cardiac events (MACE) & should treat emergently without regard to cardiac biomarkers
  • NSTEACS patients have variable risk profiles classified using one of several risk assessment tools (ex: TIMI risk score → estimates risk of MACE by 14d)

Treatment Goals: early restoration of blood flow to infarct-related artery to prevent infarct expansion (MI) or prevent complete occlusion & MI (in UA); prevention of death & complications; prevention of coronary artery reocclusion; relief of ischemic chest discomfort (Circulation 2004;110:e82; Circulation 2007;116:e148; Circulation 2008;117:296)

Approach to Treatment

(Circulation ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.

This site uses cookies to provide, maintain and improve your experience. MHE Privacy Center Close